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Summary Forty-six previously untreated patients with advanced ovarian cancer were treated with combi-
nation chemotherapy comprising cisplatin 80mgm 2 i.v. and cyclophosphamide 1 gm-2 i.v. every 28 days for
5 cycles. Eighty-five percent of patients received more than 75% of the calculated doses, and of 43 evaluable
patients, a complete response was achieved in 31 (72%), a partial response in 4 (9.3%) and 8 patients had
static or progressive disease. The actuarial survival of the whole group is 60% at a median follow-up of 2
years. Twenty-four patients in complete clinical or pathological remission were then treated with whole
abdominal radiotherapy 2,500cGy followed by a pelvic boost of 2,000cGy. The pelvic boost was omitted in 3
patients, and the overall radiotherapy treatment time extended in a further 4 patients on account of
myelosuppression. The actuarial survival of the 24 patients receiving both treatments at a median of 30
months follow-up is 75%. In the 10 patients with negative second-look procedures completing both
treatments there have been no tumour related deaths at a median follow-up of 33 months.
Ovarian cancer shows a rising incidence in Western Europe
and the USA, and is the 4th commonest cause of death from
cancer in women (Muir & Nectouse, 1978). The development
and assessment of treatment approaches has been impaired
by variations in staging methods which have altered the
distribution of cases between FIGO stages I-IV over the last
10 years; however, ovarian cancer remains a disease of the
abdomen in over 80% of cases. The extent of primary
surgical debulking is an important prognostic factor
(Griffiths et al., 1979; Hacker et al., 1983), but where the
disease is advanced chemotherapy is required in addition.
For many years alkylating agents were used alone giving
response rates ranging from 10 to 65% and a response
duration of the order of 12 months (Young, 1979), but no
clear prolongation of survival (Richardson et al., 1985a,b).
When cisplatin is incorporated in combination chemo-
therapy schedules, response rates of the order of 70% have
been achieved (Green & Young, 1983; Richardson et al.,
1985a,b) and there is now evidence of a modest improve-
ment of survival (Dembo, 1986). The highest recorded
response rate (92%) and a median survival in excess of 2
years have been reported using the four drugs cyclo-
phosphamide, hexamethylmelamine, adriamycin and cisplatin
(CHAP) (Neijt et al., 1984). However, the.toxicity of this
regime was severe and two randomised trials have shown
that the combination of cisplatin and cyclophosphamide
gives equivalent progression-free survival and overall survival
with much reduced toxicity (Edmonson et al., 1985; Neijt et
al., 1985).
The place of radiotherapy has proved harder to define, but
the beneficial effect seems confined to small volume disease
as reported by Dembo & Bush (1983) who showed a 78% 6-
year survival in stages Ib, II and 'asymptomatic' stage III
patients with abdominal and pelvic irradiation, and Smith et
al. (1975) and Martinez et al. (1985) also showed that
irradiation was associated with prolonged survival in stages
1-111 patients. Histopathology, age and residual disease
volume were important prognostic factors. However, the
staging criteria used in these studies were inadequate by
present day standards, and there was a high rate of relapse
outside the pelvis.
In view of this evidence that whole abdominal irradiation
may control small volume disease, the role ofthis modality has
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been examined in patients who have had a good response to
chemotherapy but may still have residual disease.
Hainsworth et al. (1983) found abdominopelvic irradiation
after chemotherapy to be poorly tolerated, and only 7 out of
17 patients completed the planned course principally because
of myelosuppression. In other small series employing a
variety of cytotoxic drug combinations, the treatment which
could be administered was limited by myelosuppression and
bowel toxicity (Steiner et al., 1985; Hacker et al., 1985; Rizel
et al., 1985; Greiner et al., 1984).
In the present study patients were treated with five cycles
of the two most active drugs, cyclophosphamide and cis-
platin, to achieve a complete remission followed in patients
with absence of macroscopic residual disease by radiotherapy
to the whole abdomen and pelvis given in small fractions.
Consolidation radiation therapy was therefore employed at
the optimum time when residual tumour volume was small
(Tubiana, 1983).
Patients and methods
Forty-six patients were treated between July 1983 and
February 1985 and their characteristics are shown in Table I.
All patients had histologically proven epithelial tumour, and
patients with 'borderline' malignancy were not eligible.
Exclusion criteria were - age over 70yrs, ischaemic heart
disease, other malignancy and performance status (WHO) 3
or 4.
Chemotherapy
The combination chemotherapy regime consisted of cisplatin
80mgm 2 infused over 1 h and cyclophosphamide 1 gm-2
i.v. as a bolus. Pre- and post-hydration was given to achieve
a minimum urine output of 200mlh-1 to minimize renal
damage. Creatinine clearance, serum magnesium and blood
counts were monitored, and treatment was administered at 4
weekly intervals to a total of 5 courses.
Radiotherapy
Radiotherapy was given to the whole abdomen including the
diaphragm using parallel opposed fields to a mid plane dose
of 2,500cGy in 25 fractions to patients who were in com-
plete clinical or pathological remission. All patients were
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Table I Patient characteristics (n=46).
Mean age: 56yr (range 34-70)
Stage: lb
Ic
II
III
IV
Differentiation
Performance status (WHO)
TAH/BSO completed- 33
Bulk pre-surgery
pre-chemotherapy
XXX =maximum tumour
XX=3-9cm; X= <2cm.
poor
moderate
well
0
2
xxx
xx
x
xxx
xx
x
0
5
6
25
9
20
20
6
23
18
5
29
10
7
4
17
12
13
diameter >10cm;
treated on an 8 Mev linear accelerator at 120cm FSD by the
open field technique. In the first phase, the whole abdomen
was treated by parallel opposed fields extending from 1 cm
above the diaphragmatic domes at expiration to the obtura-
tor foramina lower borders. A mid-plane tumour dose of
2,500cGy was given in 25 fractions in 5 weeks. The kidneys
were shielded from the posterior field at a tumour dose of
1,500cGy, but no liver shielding was used. This was followed
by a pelvic boost to a mid plane dose of 2,000cGy in ten
daily fractions over 12 to 14 days by 14-16cm wide fields
extending from L5 to the lower borders of the obturator
foramina.
Evaluation
Response was assessed after chemotherapy and before radio-
therapy and consisted of pathological staging in 18 (12
laparotomy, 6 laparoscopy) and clinical restaging, including
CT and ultrasound scans in 29. A complete response (CR)
was defined as the disappearance of all known disease
determined by two observations not less than 4 weeks apart,
and a partial response as a 50% or more decrease in the
product of two perpendicular diameters of all lesions, in the
absence of evidence of disease progression. Static disease was
defined as a decrease in total tumour size by less than 50%
or an increase by less than 25%, in the absence of any new
lesions. Survival curves were calculated from the date chemo-
therapy was started, and were calculated by the method of
Kaplan-Meier (Armitage, 1971).
therapy 31 (72%) were in complete remission, 4 (9.3%)
showed a partial response, 4 static disease, and 4 progressive
disease. Thirteen of these complete responses were assessed
at second-look procedures and the remainder based on
clinical and radiological assessment. Six second-look laparo-
scopies and 12 second-look laparotomies were carried out on
patients in clinical complete remission, with no evidence of
disease found in 13, a partial response in 2, static disease in
2 and progressive disease in one. Further tumour debulking
was carried out in 4 patients.
Survival
Twenty patients have died and a further 3 patients have
relapsed but remain alive at 27, 36 and 37 months. One
patient died of a pulmonary embolism, one of progressive
cachexia shortly after a third laparotomy which showed
intra-abdominal fibrosis but no evidence of malignancy, and
the remaining 18 patients of progressive malignancy. Second-
line cytotoxic chemotherapy was given to 12 patients, and
only one achieved a partial response.
The median survival of the entire group (Figure 1) has not
been reached at a median follow-up of 2 years and the
actuarial survival at that time is 60%. The 9 patients with
Stage IV disease had a median survival of 12 months. The
median survival of the patients not achieving complete
response was also 12 months, whereas of those 31 patients
achieving a clinical or pathological complete response only 4
have relapsed within 2 years. Table II shows the risk of
relapse by FIGO stage, residual disease volume, and
response.
Subset analysis
Twenty-four patients in complete clinical or pathological
complete remission proceeded to whole abdominopelvic irra-
diation. Three further patients with static disease (1 patient)
and partial response (2 patients) were also given abdomino-
pelvic irradiation at full dose and died 8, 7 and 6 months
later, respectively. Three patients have refused radiotherapy.
Of these 24 patients the actuarial disease free survival at
30 months was 75% (Figure 2), there being 4 deaths at 14,
20, 29 and 30 months. All three relapses were in both the
abdomen and pelvis, and the fourth patient had the cachexia
and extensive intra-abdominal fibrosis referred to above,
with no tumour found at laparotomy just before death. This
patient, who presented with Stage IV disease, was the only
one out of 10 patients with negative second-look procedures
completing abdominopelvic radiotherapy who has died at a
median follow-up of 33 months. Five of these 10 patients
with negative second look operations had disease >2cm left
after primary surgery. When the patients with Stage I and II
disease are excluded, and the analysis restricted to that
subset of 15 patients with Stage III and IV disease with
1 .0-
Results
Total abdominal hysterectomy and bilateral salpingo-
oophorectomy were completed in 33 out of 46 patients, and
omentectomy was carried out in 28 of these. Following
completion of initial surgery, only 4 patients had bulky
disease > 10cm which was not amenable to debulking
surgery, and in 25 patients reduction of disease volume down
to a maximum tumour diameter of <2cm was achieved.
Response
Of the 46 patients entered on the protocol, 3 are not eligible
for response. There was one death after the first cycle,
attributed to a pulmonary embolism, one to rapid deterio-
ration attributed to progressive disease, and one patient
refused to have any further chemotherapy after the first
cycle. Of the remaining 43, at the completion of chemo-
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Figure 1 Survival curve (upper) of all 46 patients with advanced
ovarian cancer treated with induction chemotherapy comprising
cisplatin and cyclophosphamide, and (lower) the 9 patients with
FIGO Stage IV ovarian cancer. Only one of these 9 patients
achieved a CR and received abdominopelvic radiotherapy.
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Table II Proportion of patients (n =46) relapsing by stage, residual disease and
response.
(a) Responders
Clinical assessment
CR PR Other
Pathological assessment
CR PR Other
Number relapsed
Number at risk
% relapsed
(b) Stage/Bulk
FIGO Stage
I II III IV
Residual disease'
0 X XX XXX
Number relapsed
Number at risk
% relapsed
ao =microscopic/none; X = <2cm; XX =3-9cm; XXX = >10cm.
moderate or poor histological differentiation, the actuarial
survival at 2 years was 67% (Figure 3).
The 4 patients in whom gross disease more than 10cm in
diameter was present at the start of chemotherapy were all
dead within 12 months, but there was no significant differ-
ence in actuarial survival betWeen those debulked to <5cm
and those debulked to <2cm maximum tumour diameter,
although the risk of relapse increased progressively with FIGO
stage and pre-chemotherapy residual disease (Table II).
Toxicitv
Patients generally tolerated the chemotherapy without diffi-
culty and toxicity was not excessive. Doses were reduced
below 75% of those calculated for cisplatin in 15% of cases,
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Figure 2 Relapse free survival in the 24 patients with advanced
ovarian cancer achieving a complete clinical remission with
cisplatin and cyclophosphamide followed by abdominopelvic
radiotherapy.
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Figure 3 Relapse free survival in the 15 patients with Stages III
and IV ovarian carcinoma and moderate or poor histological
differentiation given sequential chemotherapy and radiotherapy.
and for cyclophosphamide in 9% of cases. A delay of 2
weeks or more due to myelosuppression was recorded in
only 2 patients. One patient refused treatment after the first
cycle. Grade III (WHO) nausea and vomiting and alopecia
were universal, and Grade III diarrhoea was seen in 2
patients.
Out of 223 cycles of chemotherapy, the total leucocyte
count fell below 1 .0 x 109 1
1 in 10 patients (4.5% of cycles)
and a fall below 2.0 x1091 -1 was recorded in a further 30
patients (13.5% of cycles). There were transfusions given to
12 patients and no episodes of neutropenic fever. The
creatinine clearance fell below 50ml min- in 6 patients, and
this nephrotoxicity was cumulative, reaching a peak inci-
dence after cycle 4.
Four patients discontinued chemotherapy after the fourth
cycle. The radiotherapy was well tolerated by the patients
although myelosuppression was seen in most cases. A
rapid fall in the total WBC in the first week to around
2 x 109 1-1 was usually seen, but in most cases it was possible
to continue radiotherapy without this fall continuing. Sus-
pension of treatment for two or more weeks was required on
account of myelosuppression in tive other patients, but in
only one of these was treatment discontinued and the pelvic
boost omitted on account of thrombocytopenia. The median
number of treatment days delayed was 12 (mean 11.2 days,
range 9-25 days). There were no episodes of neutropenic
fever or bleeding, but one case of WHO Grade III late renal
damage, a second of Grade III elevated liver function tests
and a third of Grade III gastrointestinal toxicity were
recorded. In one case a recto-vaginal fistula developed
following abdominal irradiation, and the pelvic boost was
omitted. One further patient had extensive intraperitoneal
fibrosis as discussed above.
Discussion
We have shown that a regime consisting of aggressive
chemotherapy comprising cisplatin and cyclophosphamide
followed by a tumoricidal dose of radiation to the abdomen
and pelvis can be tolerated by a high proportion of middle-
aged women with carcinoma of the ovary. Myelosuppression
was acceptable during both the chemotherapy and radio-
therapy components of treatment. The relative lack of
toxicity seen with the radiation therapy may be related in
part to the absence of adriamycin from the induction regime.
These results show a complete response rate to chemo-
therapy of 72% which compares favourably with other
published regimes. It has been estimated that cisplatin
containing combinations prolong the median survival time in
advanced ovarian cancer by 6-12 months over those who
have never received cisplatin or its analogues (Dembo, 1986),
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although there is still controversy over the size of the effect.
This survival benefit of chemotherapy has been particularly
marked in those patients with disease debulked to a maxi-
mum residual diameter of 3 cm or less (Ozols & Young,
1984) and it is at this volume that the dose of achievable
radiation therapy reaches its optimum (Tubiana, 1983), as
the number of residual clonogenic cells is low.
In the present study the 24 patients in complete remission
given combined modality treatment (Figure 2) provide evi-
dence that the combined approach of chemotherapy and
radiotherapy may have produced a significant cohort of long
term survivors, the only death being associated with exten-
sive peritoneal fibrosis with no evidence of recurrent tumour.
This is emphasised by the subset analyses of the 10 patients
in pathological complete remission, and in the poor risk
intra-abdominal disease patients (Figure 3) given both treat-
ments. A negative second-look procedure confirms the first
requirement has been met for a treatment approach designed
to achieve prolonged survival, but almost certainly further
consolidation chemotherapy or radiation therapy is required
to improve the long term results in this disease (Sutton et al.,
1986; Cain et al., 1986). In the 3 patients given abdomino-
pelvic radiotherapy where macroscopic disease was present,
the short survival would indicate this treatment was of little
benefit in this group.
The lack of an effect of moderate tumour bulk on survival
either at presentation or after surgery may be further
evidence that the irradiation is providing a consolidation
effect to the chemotherapy, as in previous studies with
surgery and chemotherapy alone, bulk has been an impor-
tant variable in determining outcome (Williams et al., 1982).
However, the 9 patients with stage IV disease have shown a
particularly poor survival, as did those 4 in whom no
debulking was possible, and in the entire group FIGO stage
and residual disease were related to relapse. It may be that
the critical site of tumour (e.g. in bowel wall or liver) is more
important than bulk: alternatively this intensive treatment
approach has overcome an adverse factor applicable only to
these earlier studies.
The present series compares favourably in outcome to
other studies of sequential chemotherapy and radiotherapy.
Hainsworth et al. (1983) found that 15 out of 17 patients
given sub-optimal doses of chemotherapy and radiotherapy
relapsed within a median of 8 months. Rustin et al. (1987)
employed a similar approach, but omitted the boost to the
pelvis, and in 27 patients with Stage III disease, 8 of whom
were in pathological complete remission, found a median
progression free survival of 19 months. In the present study
the restriction of the 2 drug combination to 5 cycles and the
low fraction size of radiotherapy may have contributed to
the improved results.
This aggressive approach deserves further evaluation in
adequately debulked patients without visceral involvement. It
is clear that the selection of an adequate dose and schedule
of chemotherapy (Piccart et al., 1987) and of radiation
therapy (Dembo et al., 1979) is vital to achieve disease
control without excessive toxicity. However, one third of
patients may not reach this stage of treatment on account of
failure to achieve response to chemotherapy or refusal of
patients to accept the complete course of intensive treatment.
Patients with poor prognostic factors, such as Stage IV
disease, require more intensive induction chemotherapy. In
those patients responding to chemotherapy the abdomino-
pelvic radiotherapy given in the present study needs to be
compared in a randomised trial to continuing chemotherapy
or no further therapy.
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